Page 70 - Read Online

Poznyak et al. Microbiome Res Rep. 2026;5:3 Page 17 of 23

42. Rogier R, Ederveen THA, Boekhorst J, et al. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17-
and TLR4-dependent arthritis. Microbiome. 2017;5:63. DOI PubMed PMC
43. Pianta A, Arvikar S, Strle K, et al. Evidence of the immune relevance of Prevotella copri, a gut microbe, in patients with rheumatoid
arthritis. Arthritis Rheumatol. 2017;69:964-75. DOI PubMed PMC
44. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492-506. DOI
PubMed PMC
45. Seifert JA, Bemis EA, Ramsden K, et al. Association of antibodies to Prevotella copri in anti-cyclic citrullinated peptide-positive
individuals at risk of developing rheumatoid arthritis and in patients with early or established rheumatoid arthritis. Arthritis Rheumatol.
2023;75:507-16. DOI PubMed PMC
46. Wei F, Zhao M, Sun X, Ma H, Yin H, Shen X. Causal associations between gut microbiota and rheumatoid arthritis: a two-sample
Mendelian randomization study. Medicine (Baltimore). 2025;104:e42596. DOI
47. Horta-Baas G, Romero-Figueroa MDS, Montiel-Jarquín AJ, Pizano-Zárate ML, García-Mena J, Ramírez-Durán N. Intestinal dysbiosis
and rheumatoid arthritis: a link between gut microbiota and the pathogenesis of rheumatoid arthritis. J Immunol Res.
2017;2017:4835189. DOI PubMed PMC
48. Zhao T, Wei Y, Zhu Y, et al. Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities. Front
Immunol. 2022;13:1007165. DOI PubMed PMC
49. Marietta EV, Murray JA, Luckey DH, et al. Suppression of inflammatory arthritis by human gut-derived Prevotella histicola in
humanized mice. Arthritis Rheumatol. 2016;68:2878-88. DOI PubMed PMC
50. Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151:363-74. DOI PubMed
PMC
51. Balakrishnan B, Luckey D, Bodhke R, et al. Prevotella histicola protects from arthritis by expansion of allobaculum and augmenting
butyrate production in humanized mice. Front Immunol. 2021;12:609644. DOI PubMed PMC
52. Zang X, Xiao M, Yu L, et al. Prevotella copri - a potential next-generation probiotic. Food Frontiers. 2024;5:1391-409. DOI
53. Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade
immunotherapy of cancer. Genome Med. 2021;13:107. DOI PubMed PMC
54. Rooney CM, Jeffery IB, Mankia K, Wilcox MH, Emery P. Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis:
a cross-sectional and longitudinal observational study. Ann Rheum Dis. 2024;84:562-74. DOI PubMed
55. Roszyk E, Puszczewicz M. Role of human microbiome and selected bacterial infections in the pathogenesis of rheumatoid arthritis.
Reumatologia. 2017;55:242-50. DOI PubMed PMC
56. Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Signal
Transduct Target Ther. 2023;8:386. DOI PubMed PMC
57. Zádori ZS, Király K, Al-Khrasani M, Gyires K. Interactions between NSAIDs, opioids and the gut microbiota - future perspectives in the
management of inflammation and pain. Pharmacol Ther. 2023;241:108327. DOI
58. Hao Y. Gut microbiota-immune axis in the regulation of rheumatoid arthritis: from mechanism to precision probiotic strategies. Mod
Rheumatol. 2025;36:1-14. DOI PubMed
59. Hellwig M, Diel P, Eisenbrand G, et al. Dietary glycation compounds - implications for human health. Crit Rev Toxicol.
2024;54:485-617. DOI
60. Phuong-Nguyen K, McNeill BA, Aston-Mourney K, Rivera LR. Advanced glycation end-products and their effects on gut health.
Nutrients. 2023;15:405. DOI PubMed PMC
61. Shoham S, Pintel N, Avni D. Oxidative stress, gut bacteria, and microalgae: a holistic approach to manage inflammatory bowel diseases.
Antioxidants (Basel). 2025;14:697. DOI PubMed PMC
62. Ma Z, Zuo T, Frey N, Rangrez AY. A systematic framework for understanding the microbiome in human health and disease: from basic
principles to clinical translation. Signal Transduct Target Ther. 2024;9:237. DOI PubMed PMC
63. Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and human health: current understanding,
engineering, and enabling technologies. Chem Rev. 2023;123:31-72. DOI PubMed PMC
64. Wu IW, Lin CY, Chang LC, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels
in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16:420-34. DOI PubMed PMC
65. You Y, Xiang T, Yang C, et al. Interactions between the gut microbiota and immune cell dynamics: novel insights into the gut-bone axis.
Gut Microbes. 2025;17:2545417. DOI PubMed PMC
66. Ortega MA, Álvarez-Mon MA, García-Montero C, et al. Microbiota-gut-brain axis mechanisms in the complex network of bipolar
disorders: potential clinical implications and translational opportunities. Mol Psychiatry. 2023;28:2645-73. DOI PubMed PMC
67. Xie X, Chen X, Wang X, Wang S, Qi P. Dual regulatory effects of gut microbiota and their metabolites in rheumatoid arthritis: balancing
pathogenic and protective mechanisms. Front Immunol. 2025;16:1584023. DOI PubMed PMC